newsfilter
← Latest News
GlobeNewswire·

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced acquisition in the